Brokers Offer Predictions for AbbVie FY2026 Earnings

AbbVie Inc. (NYSE:ABBV) – Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of AbbVie in a report released on Monday, June 9th. Cantor Fitzgerald analyst C. Gould forecasts that the company will post earnings per share of $14.12 for the year. Cantor Fitzgerald has a “Overweight” rating and a $210.00 price target on the stock. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share.

A number of other research analysts also recently issued reports on ABBV. The Goldman Sachs Group reiterated a “neutral” rating and issued a $194.00 price target on shares of AbbVie in a research note on Tuesday, April 8th. Morgan Stanley lifted their price objective on shares of AbbVie from $241.00 to $250.00 and gave the stock an “overweight” rating in a research report on Monday, April 28th. BNP Paribas raised AbbVie to a “hold” rating in a report on Thursday, May 8th. Bank of America increased their price objective on AbbVie to $204.00 and gave the company a “hold” rating in a report on Monday. Finally, Evercore ISI increased their price target on shares of AbbVie from $204.00 to $205.00 and gave the company an “outperform” rating in a research note on Monday, April 28th. Eight investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $211.29.

AbbVie Stock Performance

Shares of ABBV opened at $190.21 on Tuesday. AbbVie has a 1 year low of $163.52 and a 1 year high of $218.66. The stock has a market capitalization of $335.98 billion, a PE ratio of 79.56, a PEG ratio of 1.62 and a beta of 0.50. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66. The stock has a 50-day simple moving average of $183.92 and a 200-day simple moving average of $187.28.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, April 25th. The company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.40 by $0.06. The business had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $12.91 billion. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.31 earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ABBV. eCIO Inc. purchased a new stake in shares of AbbVie during the first quarter worth about $182,000. Militia Capital Partners LP acquired a new stake in AbbVie during the first quarter worth approximately $126,000. CBIZ Investment Advisory Services LLC grew its stake in AbbVie by 8.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 1,006 shares of the company’s stock worth $211,000 after acquiring an additional 79 shares during the period. Invst LLC raised its holdings in AbbVie by 68.9% in the 1st quarter. Invst LLC now owns 6,454 shares of the company’s stock valued at $1,352,000 after acquiring an additional 2,633 shares during the last quarter. Finally, Modern Wealth Management LLC raised its holdings in AbbVie by 9.4% in the 1st quarter. Modern Wealth Management LLC now owns 52,808 shares of the company’s stock valued at $11,064,000 after acquiring an additional 4,544 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In other news, EVP Jeffrey Ryan Stewart sold 58,832 shares of the company’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $210.08, for a total value of $12,359,426.56. Following the sale, the executive vice president now directly owns 53,234 shares in the company, valued at $11,183,398.72. This represents a 52.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.25% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.